StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)
September 30, 2026 5:43 AM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst comments "At ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
